Compare Tractor Supply Co (TSCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tractor Supply Co vs Viatris Inc — how do they compare? Tractor Supply Co trades at $30.37 (market cap $15.89B), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Tractor Supply Co pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| TSCO | VTRS | |
|---|---|---|
Market Cap | $15.89B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.65 | $17.39 |
52-Week Low | $29.14 | $8.74 |
Enterprise Value | $22.08B | $32.00B |
Dividend Yield | 3.17% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
